Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Viruses ; 13(9)2021 08 25.
Article in English | MEDLINE | ID: mdl-34578264

ABSTRACT

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) caused by the JC virus is the main limitation to the use of disease modifying therapies for treatment of multiple sclerosis (MS). METHODS: To assess the PML risk in course of ocrelizumab, urine and blood samples were collected from 42 MS patients at baseline (T0), at 6 (T2) and 12 months (T4) from the beginning of therapy. After JCPyV-DNA extraction, a quantitative-PCR (Q-PCR) was performed. Moreover, assessment of JCV-serostatus was obtained and arrangements' analysis of non-coding control region (NCCR) and of viral capsid protein 1 (VP1) was carried out. RESULTS: Q-PCR revealed JCPyV-DNA in urine at all selected time points, while JCPyV-DNA was detected in plasma at T4. From T0 to T4, JC viral load in urine was detected, increased in two logarithms and, significantly higher, compared to viremia. NCCR from urine was archetypal. Plasmatic NCCR displayed deletion, duplication, and point mutations. VP1 showed the S269F substitution involving the receptor-binding region. Anti-JCV index and IgM titer were found to statistically decrease during ocrelizumab treatment. CONCLUSIONS: Ocrelizumab in JCPyV-DNA positive patients is safe and did not determine PML cases. Combined monitoring of ocrelizumab's effects on JCPyV pathogenicity and on host immunity might offer a complete insight towards predicting PML risk.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Immunologic Factors/therapeutic use , JC Virus/drug effects , Leukoencephalopathy, Progressive Multifocal/etiology , Multiple Sclerosis/drug therapy , Viral Load/drug effects , Adult , Capsid Proteins/genetics , DNA, Viral/genetics , Female , Humans , JC Virus/classification , JC Virus/genetics , JC Virus/pathogenicity , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/urine , Male , Middle Aged , Multiple Sclerosis/blood , Multiple Sclerosis/complications , Multiple Sclerosis/urine , Phylogeny , Risk Assessment , Viremia/drug therapy
2.
Mult Scler Relat Disord ; 41: 102008, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32087593

ABSTRACT

BACKGROUND: The risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham virus (JCPyV), is the main limitation to the use of natalizumab, highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Establishing the PML risk against expected benefits represents an obligatory requirement of MS treatment algorithm. In order to achieve this goal, the aims of this study were to establish if JCPyV-DNA detection and non-coding control region (NCCR) arrangements could play a role of biomarkers, supporting anti-JCPyV antibodies measurement, actually the only parameter for PML risk stratification. METHODS: Thirty RRMS patients in treatment with natalizumab were enrolled. Urine and blood samples were collected according to this calendar: baseline (T0), 4 (T1), 8 (T2), 12 (T3), 16 (T4), 20 months (T5) after beginning of natalizumab therapy. After JCPyV DNA extraction, a specific quantitative-PCR (Q-PCR) and arrangements' analysis of NCCR and Viral Capsid Protein 1 (VP1) were carried out. RESULTS: Q-PCR detected JCPyV DNA in urine and blood from baseline (T0) to 20 natalizumab infusions (T5), although JC viral load in urine was significantly higher compared to viremia, at all selected time points. A contextual analysis of the anti-JCPyV-antibodies versus JCPyV-DNA detection revealed that viral DNA preceded the antibodies' presence in the serum. During the first year of natalizumab treatment, sequences isolated from blood displayed an archetype JCPyV NCCR structure with the occurrence of point mutations, whereas after one year NCCR re-organizations were observed in plasma and PBMC with duplication of NF-1 binding site in box F, duplication of box C and partial or total deletion of box D. VP1 analysis showed the amino acid change mutation S269F in plasma and S267L in PBMC, involving the receptor-binding region of VP1. Phylogenetic analysis suggested a stability and a similarity across different isolates of the JCPyV VP1. CONCLUSIONS: We highly recommend considering JCPyV-DNA detection and NCCR re-organizations as viral biomarkers in order to accurately identify JCPyV-infected patients with a specific humoral response not yet detectable and to identify NCCR arrangements correlated with the onset of neurovirulent variants.


Subject(s)
Antibodies, Viral/blood , DNA, Viral , Immunologic Factors/administration & dosage , JC Virus/immunology , Leukoencephalopathy, Progressive Multifocal/diagnosis , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Natalizumab/administration & dosage , Adult , Biomarkers , Capsid Proteins , DNA, Viral/blood , DNA, Viral/isolation & purification , DNA, Viral/urine , Female , Humans , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Male , Polymerase Chain Reaction , Risk Assessment , Young Adult
3.
Diagn Microbiol Infect Dis ; 95(3): 114859, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31320237

ABSTRACT

OBJECTIVE: To assess the predictive value of JC virus (JCV) PCR in cerebrospinal fluid (CSF) in the diagnosis of progressive multifocal leukoencephalopathy (PML). METHODS: We conducted a retrospective database query to identify patients with positive CSF JCV PCR. Clinical features, final diagnosis and quantitative PCR results were obtained. RESULTS: A positive CSF JCV PCR had a PPV of 10.4% for the diagnosis of PML. A weakly positive PCR had a PPV of 1.6%, whereas a moderately to highly positive PCR had a PPV of 92.3%. A PPV of 0.0% was observed in immunocompetent patients and in patients without compatible clinical or radiological features. CONCLUSIONS: A false-positive CSF JCV PCR is highly prevalent in our clinical practice. This test should be reserved for patients with a clinical suspicion of PML and the quantitative result of the PCR should be taken into account when making the diagnosis of PML.


Subject(s)
JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/cerebrospinal fluid , Leukoencephalopathy, Progressive Multifocal/diagnosis , Polymerase Chain Reaction , Viral Load/methods , DNA, Viral/blood , DNA, Viral/cerebrospinal fluid , DNA, Viral/urine , False Positive Reactions , Humans , JC Virus/genetics , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/urine , Polyomavirus Infections/cerebrospinal fluid , Polyomavirus Infections/diagnosis , Predictive Value of Tests , Retrospective Studies
4.
J Neurovirol ; 25(4): 608-611, 2019 08.
Article in English | MEDLINE | ID: mdl-30949974

ABSTRACT

West Nile virus is a notable cause of neuroinvasive disease, damage to the central nervous system, or even death. In this study, using metagenomics analysis and quantitative real-time PCR validation, we identified a JC virus infection in urine and cerebrospinal fluid samples of a West Nile virus patient with severe neurological symptoms and extended disease. JC virus is known to be involved in neurological complications, especially in immunocompromised individuals thus suggesting that the coinfection with JC virus is involved with the West Nile virus infection persistence and severe symptoms. JC virus was identified in urine samples from additional West Nile virus patients via quantitative real-time PCR, however, JC virus was not found in any cerebrospinal fluid samples of West Nile virus patients, suggesting that JC virus does not regularly infect the central nervous system of WNV patients. Overall, this study highlights the importance of identifying infection by opportunistic viruses in already-diagnosed patients and highlights the advantages of next-generation sequencing and metagenomics for viral diagnosis.


Subject(s)
JC Virus/genetics , Leukoencephalopathy, Progressive Multifocal/virology , West Nile Fever/virology , West Nile virus/genetics , Acute Disease , Coinfection , DNA, Viral/cerebrospinal fluid , DNA, Viral/genetics , DNA, Viral/urine , High-Throughput Nucleotide Sequencing , Humans , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/cerebrospinal fluid , Leukoencephalopathy, Progressive Multifocal/diagnosis , Leukoencephalopathy, Progressive Multifocal/urine , Metagenomics , RNA, Viral/cerebrospinal fluid , RNA, Viral/genetics , RNA, Viral/urine , Real-Time Polymerase Chain Reaction , West Nile Fever/cerebrospinal fluid , West Nile Fever/diagnosis , West Nile Fever/urine , West Nile virus/isolation & purification
5.
Biomed Res Int ; 2018: 5297980, 2018.
Article in English | MEDLINE | ID: mdl-29682547

ABSTRACT

Although natalizumab (anti-α4 integrin) represents an effective therapy for relapsing remitting multiple sclerosis (RRMS), it is associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML), caused by the polyomavirus JC (JCV). The aim of this study was to explore natalizumab-induced phenotypic changes in peripheral blood T-lymphocytes and their relationship with JCV reactivation. Forty-four patients affected by RRMS were enrolled. Blood and urine samples were classified according to natalizumab infusion number: 0 (N0), 1-12 (N12), 13-24 (N24), 25-36 (N36), and over 36 (N > 36) infusions. JCV-DNA was detected in plasma and urine. T-lymphocyte phenotype was evaluated with flow cytometry. JCV serostatus was assessed. Ten healthy donors (HD), whose ages and sexes matched with the RRMS patients of the N0 group, were enrolled. CD8 effector (CD8 E) percentages were increased in natalizumab treated patients with detectable JCV-DNA in plasma or urine compared to JCV-DNA negative patients (JCV-) (p < 0.01 and p < 0.001, resp.). Patients with CD8 E percentages above 10.4% tended to show detectable JCV-DNA in plasma and/or urine (ROC curve p = 0.001). The CD8 E was increased when JCV-DNA was detectable in plasma or urine, independently from JCV serology, for N12 and N24 groups (p < 0.01). As long as PML can affect RRMS patients under natalizumab treatment with a negative JCV serology, the assessment of CD8 E could help in the evaluation of JCV reactivation.


Subject(s)
CD8-Positive T-Lymphocytes/drug effects , DNA, Viral/blood , DNA, Viral/urine , JC Virus/drug effects , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/virology , Natalizumab/therapeutic use , Adult , Female , Humans , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/drug therapy , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/urine
6.
J Int Med Res ; 46(3): 1024-1032, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29322824

ABSTRACT

Objectives Human JC polyomavirus (JCPyV) infection has an increased risk of developing progressive multifocal leukoencephalopathy (PML). Different JCPyV subtypes differ in the virulence with which they cause PML. Currently, the JCPyV infection status and subtype distribution in patients with human immunodeficiency virus-1 (HIV-1) in China are still unclear. This study aimed to investigate the epidemiology and subtype distribution of JCPyV in HIV-1-infected patients in China. Methods Urine samples from 137 HIV-1-infected patients in Zhejiang Province in China were tested for the presence of JCPyV DNA. The detected VP1 sequences were aligned and analysed using BioEdit and MEGA software. Results Among urine samples from HIV-1-infected patients, 67.2% were positive for JCPyV DNA (92/137). Primarily, the type 7 strains of JCPyV were detected, among which 45.5% (15/33) were subtype 7A, 30.3% (10/33) were 7B, and 24.2% (8/33) were 7C. Six nucleotide mutations, as well as one amino acid substitution, were isolated from the patients. Conclusions Urine samples from HIV-1-infected patients from Zhejiang Province show a high JCPyV infection rate. The most common JCPyV strains are subtypes 7A, 7B, and 7C.


Subject(s)
Anti-HIV Agents/therapeutic use , DNA, Viral/genetics , HIV Infections/drug therapy , JC Virus/genetics , Polymorphism, Genetic , Adult , Aged , Aged, 80 and over , Amino Acid Substitution , Antiretroviral Therapy, Highly Active , China , Cohort Studies , Coinfection , DNA, Viral/urine , Female , Genotype , HIV Infections/ethnology , HIV Infections/urine , HIV Infections/virology , HIV-1/drug effects , HIV-1/growth & development , Humans , JC Virus/classification , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/diagnosis , Leukoencephalopathy, Progressive Multifocal/ethnology , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Male , Middle Aged , Molecular Typing , Polyomavirus Infections/diagnosis , Polyomavirus Infections/ethnology , Polyomavirus Infections/urine , Polyomavirus Infections/virology
7.
Mult Scler Relat Disord ; 19: 96-98, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29182995

ABSTRACT

Cocaine abuse may cause stroke, metabolic or multifocal inflammatory leukoencephalopathy. We described a patient with cocaine abuse who presented with Balo's type acute multifocal leukoencephalopathy. Magnetic Resonance Imaging (MRI) of the brain showed onion like patchy concentric ring enhancement on T1-weighted MRI with gadolinium. Balo's Concentric Sclerosis like radiological findings related to cocaine has not been reported. Levamisole is now frequently used as an ingredient in cocaine and may cause leukoencephalopathy. It is recommended to check urine levamisole levels in patients with cocaine-induced leukoencephalopathy with or without mimicking Balo's Concentric Sclerosis. On the other hand, it is also possible that the cocaine use was coincidental and this was a demyelinating case arising de novo in patient who uses cocaine.


Subject(s)
Adjuvants, Immunologic/toxicity , Cocaine-Related Disorders/complications , Diffuse Cerebral Sclerosis of Schilder/chemically induced , Leukoencephalopathy, Progressive Multifocal/chemically induced , Levamisole/toxicity , Adult , Diffuse Cerebral Sclerosis of Schilder/diagnostic imaging , Diffuse Cerebral Sclerosis of Schilder/urine , Follow-Up Studies , Humans , Leukoencephalopathy, Progressive Multifocal/diagnostic imaging , Leukoencephalopathy, Progressive Multifocal/urine , Male , Young Adult
8.
J Neurovirol ; 24(3): 305-313, 2018 06.
Article in English | MEDLINE | ID: mdl-29243131

ABSTRACT

In immunocompromised individuals, especially in patients with T cell immunodeficiency, reactivation of JCPyV can cause serious life-threatening diseases. Nowadays, HIV infection is one of the most important factor for reactivation of JCPyV and the development of of the progressive multifocal leukoencephalopathy (PML). Mutations in the outer loops of the VP1 region can lead to the selection of the viral variants with changed tropism and increased pathological potential. The aims of this study were to determine sequence variation and amino acid changes within VP1 loops and the structure of non-coding control region (NCCR) of urinary excreted JCPyV isolates among HIV-infected patients and healthy donors. Single urine samples from 114 HIV-infected patients and 120 healthy donors were collected. PCR was performed for amplification of VP1 and NCCR. Amplified fragments were directly sequenced and analyzed by using bioinformatics tools. Nucleotide substitutions were detected within DE and EF loops and in the ß-sheets of both studied groups. In HIV-infected patients group, 70% of mutations were detected within receptor domains. Among healthy donors, one mutation was identified within ß-sheets while the remaining were located within receptor domains. The most prevalent mutation was L157V in both groups. Analysis of NCCR revealed that all isolates had archetype structure with some minor changes. Since single point mutations at specific place within outer loop of VP1 region can cause formation of variants with changed receptor specificity, identification of these mutations in HIV-infected patients can help to single out those with higher risk for development of polyomavirus-associated diseases.


Subject(s)
Anti-HIV Agents/therapeutic use , Capsid Proteins/genetics , HIV Infections/virology , JC Virus/genetics , Leukoencephalopathy, Progressive Multifocal/virology , Polyomavirus Infections/virology , Adult , Aged , Amino Acid Substitution , Antiretroviral Therapy, Highly Active , Capsid Proteins/chemistry , Capsid Proteins/metabolism , Case-Control Studies , Coinfection , Female , Gene Expression , HIV/drug effects , HIV/growth & development , HIV/pathogenicity , HIV Infections/urine , Humans , JC Virus/pathogenicity , Leukoencephalopathy, Progressive Multifocal/pathology , Leukoencephalopathy, Progressive Multifocal/urine , Male , Middle Aged , Mutation , Polyomavirus Infections/pathology , Polyomavirus Infections/urine , Protein Structure, Secondary , Virus Activation
9.
J Neurovirol ; 22(6): 871-875, 2016 12.
Article in English | MEDLINE | ID: mdl-27198748

ABSTRACT

Sixty-three natalizumab-treated patients with relapsing multiple sclerosis were screened for JC polyomavirus (JCV) viruria. Urinary-positive patients were longitudinally sampled for up to 24 weeks. Using methods that distinguish encapsidated virus from naked viral DNA, 17.5 % of patients were found to excrete virus, consistent with the prevalence of urinary excretion in the general population. Unexpectedly, urinary excretion was predominantly seen (>73 %) in patients with high JC antibody index (≥2.0). Active JCV infection, therefore, tends to occur in natalizumab patients that carry a high risk factor for the development of disease, directly linking JC infection to the risk factors for PML development.


Subject(s)
DNA, Viral/urine , Immunologic Factors/therapeutic use , JC Virus/pathogenicity , Leukoencephalopathy, Progressive Multifocal/drug therapy , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Natalizumab/therapeutic use , Antibodies, Viral/urine , Humans , JC Virus/immunology , Leukoencephalopathy, Progressive Multifocal/etiology , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Longitudinal Studies , Multiple Sclerosis, Relapsing-Remitting/complications , Multiple Sclerosis, Relapsing-Remitting/urine , Multiple Sclerosis, Relapsing-Remitting/virology , Risk Factors , Urinalysis
10.
Eur J Neurol ; 23(1): 182-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26498276

ABSTRACT

BACKGROUND AND PURPOSE: Progressive multifocal leukoencephalopathy (PML) cases have arisen amongst multiple sclerosis patients treated with natalizumab. Our objective was to gain a better understanding of the mechanisms that underlie the John Cunningham virus (JCV) infection which causes PML. METHODS: A study was made of (i) the quarterly JCV DNA levels in peripheral blood mononuclear cells (PBMCs), serum and urine samples in 100 multiple sclerosis patients during their natalizumab treatment (3-39 months), (ii) the association between human leukocyte antigen (HLA) class II and the previous viral detection and (iii) the identification of the JCV variants in those patients suspected of having PML. RESULTS: (i) JCV DNA in PBMCs and/or serum was detected in 23% of our cohort. Patients with an intermittent JCV excretion in urine had a significant increase of the viral load and prevalence in this compartment during natalizumab treatment. (ii) The frequency of the DRB1*07/DQA1*02:01/DQB1*02:02 haplotype tended to be higher in patients with detectable versus undetectable JCV DNA in PBMCs (P(corrected) = 0.108). (iii) The variants in PBMCs and serum of the non-PML patient matched the archetype. In the patient with non-fatal PML, the archetype and the same neurotropic variant in PBMCs, serum and cerebrospinal fluid was identified at the time PML was diagnosed, whereas in the patient with a worse PML prognosis, four neurotropic variants in the three previous compartments were found by the PML diagnosis. CONCLUSIONS: The detection of the neurotropic variant in blood during natalizumab treatment could be critical in the prevention of the development of severe PML, since this variant appears simultaneously with the clinical symptoms of PML and mutates quickly.


Subject(s)
DNA, Viral/blood , Immunologic Factors/therapeutic use , JC Virus , Leukoencephalopathy, Progressive Multifocal/blood , Multiple Sclerosis/blood , Natalizumab/therapeutic use , Adult , DNA, Viral/urine , Female , Humans , Immunologic Factors/adverse effects , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Male , Middle Aged , Multiple Sclerosis/drug therapy , Multiple Sclerosis/urine , Natalizumab/adverse effects
11.
J Neurovirol ; 18(5): 411-5, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22585288

ABSTRACT

Natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis (MS) occurred in two individuals also treated with interferon ß1a, raising concerns about the interaction of these disease-modifying agents and leading to the recommendation to avoid their concomitant administration. However, type I interferons are antiviral. Using a real-time quantitative polymerase chain reaction for the detection and quantification of the John Cunningham virus (JCV), DNA in peripheral blood mononuclear cells (PBMCs), and urine in MS patients, we tested the hypothesis that MS disease-modifying drugs (DMD) qualitatively and quantitatively alter JCV prevalence and viral copy numbers. Two hundred thirty-nine patients were enrolled in a cross-sectional study in which blood and urine specimens were collected at a single time and 37 newly diagnosed, treatment-naïve MS patients were enrolled in a longitudinal study in which specimens were obtained at diagnosis and 6 months after treatment initiation. JCV DNA was detected in PBMCs of only two patients (0.07 %), but was commonly detected in the urine (46.8 %) in this population. There was no effect of DMDs on blood or urinary JCV prevalence or viral copy numbers with either glatiramer acetate (Copaxone®) or interferon-ß therapy (Avonex®, Betaseron®, or Rebif®). The small number of patients on other therapies precluded meaningful comment about their effects. No obvious effect of the platform DMDs on JCV prevalence was observed even for the interferon-ßs.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Interferon-beta/therapeutic use , JC Virus/drug effects , Leukoencephalopathy, Progressive Multifocal/drug therapy , Multiple Sclerosis/drug therapy , Adolescent , Adult , Aged , Cell Migration Inhibition , Cross-Sectional Studies , DNA, Viral/genetics , Drug Therapy, Combination , Female , Glatiramer Acetate , Humans , JC Virus/genetics , JC Virus/growth & development , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/virology , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Male , Middle Aged , Multiple Sclerosis/blood , Multiple Sclerosis/urine , Multiple Sclerosis/virology , Natalizumab , Peptides/therapeutic use , Polymerase Chain Reaction , Viral Load/drug effects
12.
J Neuroimmune Pharmacol ; 7(3): 665-72, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22585413

ABSTRACT

The risk of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab for multiple sclerosis (MS) is a serious concern. The presence of anti-JC virus antibodies is a risk factor for PML development, but 2.5 % of the patients result falsely-negative, while the prognostic relevance of testing JCV-DNA in biological fluids of treated patients is debated. Aim of this work was to evaluate the utility of testing JCV-DNA, together with anti-JCV antibodies, in biological samples of treated patients as a tool for PML risk stratification. 126 subjects from 5 MS Centers in Italy were included in the study. We performed a cross-sectional study in 63 patients testing JCV-DNA in blood, peripheral blood cells and urine. We longitudinally assessed the presence of JCV-DNA in a cohort of 33 subjects, one of which developed PML. We could test retrospectively serum samples from another PML case occurred during natalizumab therapy. Anti-JCV antibodies and urinary JCV-DNA were both tested in 73 patients. No changes in JCV-DNA status occurred during natalizumab treatment. The subject who developed PML in the longitudinal cohort had detectable JCV-DNA in urine at all time-points while serum or blood from both PML patients were always negative before the onset of disease and, in one case, after. Four subjects with JCV-DNA in urine and undetectable anti-JCV antibodies were retested for anti-JCV antibodies and three out of four resulted positive. In conclusion, testing JCV-DNA in urine is complementary to testing anti-JCV antibodies in identifying patients at risk of PML.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , DNA, Viral/urine , JC Virus/metabolism , Leukoencephalopathy, Progressive Multifocal/diagnosis , Leukoencephalopathy, Progressive Multifocal/urine , Adult , Biomarkers/urine , Cross-Sectional Studies , Diagnostic Tests, Routine , Female , Humans , Leukoencephalopathy, Progressive Multifocal/drug therapy , Longitudinal Studies , Male , Middle Aged , Natalizumab , Retrospective Studies , Risk Factors , Young Adult
13.
J Neurovirol ; 18(1): 55-61, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22281875

ABSTRACT

Polyomavirus JC (JCV) reactivation causing progressive multifocal leukoencephalopathy is a main concern during biological therapies. Here, JCV reactivation in patients suffering from immune-mediated diseases after a long-term treatment with anti-tumor necrosis factor alpha (TNF-α) inhibitor infliximab was investigated. Peripheral mononuclear blood cells (PBMC), plasma and urine samples were obtained from 61 immune-mediated diseases patients treated or not with infliximab in combination with steroid and other immunomodulators and from 20 healthy donors. JCV DNA was transiently detected in 12 PBMC of 40 patients at different doses of infliximab with a higher prevalence than that of the 21 patients untreated. Conversely, a stable JCV positivity in urine of treated and untreated patients was detected. Sequencing the noncoding control region (NCCR), all samples exhibited the archetype structure with few mutations in transcriptional factor binding regions. The consequence of anti-TNF-α treatment on viral persistence was examined monitoring Torquetenovirus viremia and investigating the TNF-α-induced microRNA regulators of transcriptional factors, with a binding site on NCCR. Although infliximab treatment in this study did not affect directly JCV reactivation, further investigation on host factor(s) regulated by it will be of warranty in the understanding the mechanism(s) that may affect viral persistence.


Subject(s)
Antibodies, Monoclonal/adverse effects , JC Virus/genetics , Leukocytes, Mononuclear/virology , Leukoencephalopathy, Progressive Multifocal/virology , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Case-Control Studies , Female , Humans , Immunologic Factors/administration & dosage , Immunologic Factors/therapeutic use , Infliximab , JC Virus/pathogenicity , Leukocytes, Mononuclear/immunology , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/immunology , Leukoencephalopathy, Progressive Multifocal/urine , Male , Middle Aged , Risk Assessment , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology , Virus Activation/drug effects , Virus Activation/immunology
14.
Ann Neurol ; 68(3): 304-10, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20737514

ABSTRACT

OBJECTIVE: Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab-treated multiple sclerosis (MS) patients to predict the risk of progressive multifocal leukoencephalopathy (PML). METHODS: A total of 12,850 blood and urine samples from nearly 1,400 patients participating in natalizumab clinical trials were tested for JCV DNA using a commercially available quantitative polymerase chain reaction (qPCR) assay. A subset of these samples was also tested using a more sensitive qPCR assay developed at the National Institutes of Health (NIH). RESULTS: At the time natalizumab dosing was suspended, JCV DNA was detected in plasma by the commercial assay in 4 of 1,397 (0.3%) patients; the NIH assay confirmed these positive samples and detected JCV DNA in an additional 2 of 205 (1%) patients who tested negative with the commercial assay. None of these 6 JCV DNA positive patients developed PML. In a 48-week study testing the safety of natalizumab redosing, JCV DNA was detected in plasma of 6 of 1,094 (0.3%) patients, none of whom developed PML. Urine at baseline and week 48 was assessed in 224 patients; 58 (26%) were positive at baseline, and 55 (25%) were positive after 48 weeks of natalizumab, treatment. JCV DNA was not detected in peripheral blood mononuclear cells from any of these 1,094 patients before or after natalizumab treatment. In 5 patients who developed PML, JCV DNA was not detected in blood at any time point before symptoms first occurred. INTERPRETATION: Measuring JCV DNA in blood or urine with currently available methods is unlikely to be useful for predicting PML risk in natalizumab-treated MS patients.


Subject(s)
Antibodies, Viral , DNA, Viral/immunology , JC Virus/immunology , Leukoencephalopathy, Progressive Multifocal , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antibodies, Viral/blood , Antibodies, Viral/therapeutic use , Antibodies, Viral/urine , Confidence Intervals , DNA, Viral/blood , DNA, Viral/urine , Enzyme-Linked Immunosorbent Assay/methods , Female , Follow-Up Studies , Humans , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/therapy , Leukoencephalopathy, Progressive Multifocal/urine , Male , Natalizumab , Statistics, Nonparametric
15.
J Clin Virol ; 48(1): 6-10, 2010 May.
Article in English | MEDLINE | ID: mdl-20335066

ABSTRACT

BACKGROUND: JC virus (JCV), the causative agent of progressive multifocal leukoencephalopathy (PML), is classified in 8 different genotypes. Previous reports have suggested a positive association between specific genotypes and PML. OBJECTIVE: To compare genotypes and adaptive mutations of JCV strains from Brazilian AIDS patients with and without PML. STUDY DESIGN: The VP1 region of JCV was amplified by polymerase chain reaction from cerebrospinal fluid samples from 51 patients with PML and from urine samples of 47 patients with AIDS without central nervous system disease. Genotyping was done by phylogenetic analysis. Amino acid replacement and selection pressures were also investigated. RESULTS: JCV genotype frequency distributions showed that genotypes 2 (32.7%), 1 (26.5%) and 3 (23.5%) were the most prevalent. Genotype 1 had a positive association (p<0.0001) and genotype 3 showed an inverse association (p<0.001) with PML. A previously undescribed point mutation at residue 91 (L/I or L/V) and (L/P), non-genotype-associated, was found in 5/49 (10.2%) and 2/47 (4.3%) JCV sequences from PML and non-PML patients, respectively. This mutation was under positive selection only in PML patients. A previously described substitution of T-A in position 128 showed a significant difference between PML and non-PML cases (70% versus 16%, respectively, p<0.0005). CONCLUSION: In Brazilian patients with AIDS, JCV genotype 1 showed a strong association with PML (p<0.0001) and JCV genotype 3 showed an inverse association with PML. The possible association of aminoacids substitution in residues 91 and 128 with PML in patients with AIDS must be further investigated.


Subject(s)
HIV Infections/virology , JC Virus/genetics , Leukoencephalopathy, Progressive Multifocal/virology , Amino Acid Substitution , Bayes Theorem , Brazil , Capsid Proteins/genetics , Chi-Square Distribution , DNA, Viral/analysis , Genotype , HIV Infections/complications , Humans , Leukoencephalopathy, Progressive Multifocal/cerebrospinal fluid , Leukoencephalopathy, Progressive Multifocal/complications , Leukoencephalopathy, Progressive Multifocal/urine , Monte Carlo Method , Phylogeny , Sequence Analysis, DNA
17.
J Neurovirol ; 7(4): 345-9, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11517414

ABSTRACT

The potential transmission of JCV through the environment has been analyzed by studying the JC viruses present in raw sewage of urban populations from widely divergent geographical areas. High numbers of JCV were found. JCV was detected in 98% (51/52) of sewage samples from different geographical areas in Europe, Africa, and USA by applying a Nested-PCR procedure. The mean estimated concentration of JCV in sewage was of 10(2)-10(3) viral particles/ml. Sequence analysis shows that JCV found in environmental samples present an archetypal structure in the regulatory region as it has been described in urine samples. Cerebrospinal fluid samples (CSF) of PML (progressive multifocal leucoencephalopathy) patients were also analyzed as control samples in this study presenting tandem repeats and rearrangements at the regulatory region (RR). Sequence analysis of the intergenic region (IGR) allowed the typification and phylogenetic analysis of the JCV sequences detected in sewage. JC viral particles were also found to be stable in sewage samples at 20 degrees C for more than 70 days. This data suggest the idea that the intake of water or food contaminated with JCV could constitute a portal of entry for the virus or the viral DNA to the human organism.


Subject(s)
JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/transmission , Sewage/virology , DNA, Viral/analysis , Food Contamination , Humans , JC Virus/genetics , Leukoencephalopathy, Progressive Multifocal/urine , Molecular Sequence Data , Polymerase Chain Reaction , Shellfish/virology , Spain , Urban Population , Water Pollution
18.
Res Virol ; 149(3): 163-70, 1998.
Article in English | MEDLINE | ID: mdl-9711540

ABSTRACT

The regulatory region of progressive multifocal leukoencephalopathy-type JC virus (JCV) is rearranged in each host by a process of deletion and duplication. Of the more than 40 that have been examined, no two regulatory regions have been rearranged identically in the brain. The substrate for this rearrangement appears to be a highly stable archetypal regulatory region excreted in the urine. Its role as the transmissible form of the virus, although inferred, has never been proven. We have now amplified by PCR and cycle-sequenced the regulatory regions from 48 urinary strains of the virus. We find that the urinary form of the regulatory region is not entirely stable. Short deletions and duplications in the range of 2-16 bp were observed in seven of these strains. One of these, an inverted repeat, is a pattern of rearrangement not yet found in the brain. Two others (#208 and 230) showed a 2-bp deletion at position nos. 221 and 222, and an unusual mutation at position no. 219. These two urines were collected in different states of the USA at different times and analysed months apart. It is very unlikely that these unusual changes represent sample contamination or that they arose independently. This finding indicates that archetypal forms of the JCV regulatory region are infectious, despite their relative inactivity in tissue culture. While changes in the archetypal structure can be found, it is clear that rearrangements in the kidney are rare or rarely infectious.


Subject(s)
DNA, Viral/urine , JC Virus/genetics , Papillomavirus Infections/virology , Recombination, Genetic , Regulatory Sequences, Nucleic Acid , Tumor Virus Infections/virology , Adult , Aged , DNA, Viral/genetics , Female , HIV Infections/urine , HIV Infections/virology , Humans , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Male , Middle Aged , Multiple Sclerosis/urine , Multiple Sclerosis/virology , Papillomavirus Infections/urine , Polymerase Chain Reaction , Tumor Virus Infections/urine
19.
J Med Virol ; 52(3): 235-42, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9210030

ABSTRACT

Progressive multifocal leukoencephalopathy (PML), a viral-induced demyelinating disease, is becoming relatively common, while many diagnostic and pathogenetic aspects remain to be clarified. A study was therefore undertaken in 64 AIDS patients suffering from various neurological disorders, including PML (12 subjects), with the specific objective of searching for JC virus (JCV) DNA by nested PCR (n-PCR) in cerebrospinal fluid (CSF), peripheral blood mononuclear cells (PBMCs), and urine collected from all patients. CSF examination, CD4 and CD8 counts, neurological examinations, and neuroradiological investigations were undertaken. JCV DNA was detected in 92% of CSF specimens in 75% of the PBMCs and urine samples from the PML patients, whereas among the non-PML patients JCV DNA was not detected in any CSF samples, but was found in 10% of PBMCs and in 39% of the urine specimens. BKV and JCV DNA viruria was observed simultaneously in 6% of the AIDS patients without PML. The routine CSF tests including IgG oligoclonal bands, the Link, and Tourtellotte IgG indexes, did not show a typical pattern in PML cases. The data obtained clearly indicate that the detection of JCV DNA in CSF constitutes an efficient marker for PML diagnosis. The simultaneous presence of JCV DNA in the CSF, PBMCs, and urine samples from the PML patients, who did not differ from controls with regard to their immunosuppressive status, suggests that JCV could be carried into the central nervous system (CNS) by infected PBMCs.


Subject(s)
AIDS-Related Opportunistic Infections/virology , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/complications , Papillomavirus Infections/complications , Tumor Virus Infections/complications , AIDS-Related Opportunistic Infections/blood , AIDS-Related Opportunistic Infections/cerebrospinal fluid , AIDS-Related Opportunistic Infections/urine , Adult , DNA, Viral/analysis , Female , Humans , Leukoencephalopathy, Progressive Multifocal/blood , Leukoencephalopathy, Progressive Multifocal/cerebrospinal fluid , Leukoencephalopathy, Progressive Multifocal/urine , Male , Middle Aged , Neurologic Examination , Papillomavirus Infections/blood , Papillomavirus Infections/cerebrospinal fluid , Papillomavirus Infections/urine , Polymerase Chain Reaction , Tumor Virus Infections/blood , Tumor Virus Infections/cerebrospinal fluid , Tumor Virus Infections/urine
20.
Arch Virol ; 142(5): 875-82, 1997.
Article in English | MEDLINE | ID: mdl-9191854

ABSTRACT

Human polyomavirus JC virus (JCV), the causative agent of progressive multifocal leukoencephalopathy, is ubiquitous in humans, infecting children asymptomatically then persisting in renal tissue. Since JCV DNA can readily be detected from urine, it should be a useful tool with which to study the mode of virus transmission in humans. Based on this notion, we examined the extent to which JCV was transmitted from the American to Japanese populations in Okinawa Island, Japan. (A population of about 50 000 American soldiers and families have been stationed in Okinawa since 1945.) Four JCV types (A to D) were identified in American populations in U.S.A., whereas only type B was prevalent in elder Japanese in Okinawa who had reached adulthood by 1945. Thus, types A, C, and D served as indicators of the transmission of JCV from American to Japanese populations. We then examined whether types A, C, and D were detectable in Japanese in Okinawa aged 30-50 years who may have been in contact with Americans during childhood. However, all the 125 isolates from the younger Japanese population were type B without exception. From this finding, we concluded that JCV is rarely transmitted between human populations.


Subject(s)
Polyomavirus , Adult , DNA, Viral/urine , Humans , Japan , Leukoencephalopathy, Progressive Multifocal/urine , Leukoencephalopathy, Progressive Multifocal/virology , Middle Aged , Molecular Sequence Data , Polyomavirus/genetics , Polyomavirus/isolation & purification , Prevalence , Tumor Virus Infections/transmission , United States/ethnology
SELECTION OF CITATIONS
SEARCH DETAIL
...